After closing the Agential Cannabis conference in Bangkok last month, Stephen Murphy, founder and CEO of Prohibition Partners, considers how medicinal cannabis in the Asia-Pacific region is taking shape and what will determine leadership in the region over the next five years.
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market.
For much of the past five years, the cannabis industry has been defined by disappointment.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our understanding of its use cases, and more importantly, fill the long-maligned gap in clinical evidence.
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to be prescribed for a number of conditions in Canada.
